A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K Kumar,Robert F Cornell,Ola Landgren,Sikander Ailawadhi,Jack P Higgins,Erin K Willert,Roger Waltzman,Jianchang Lin,Yuhong Zhang,Anya R Lublinsky,Ajeeta B Dash,Michael Hanley,Divya Manoharan,Morgan Leichter,Sean Ottinger,Richard J Labotka,John Newcomb,Alexander Vorog

doi:10.1182/blood-2019-125629

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K Kumar, Robert F Cornell + Show 16 more

Open Access

https://doi.org/10.1182/blood-2019-125629

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 5

Affiliation: Mayo Clinic, Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, Jacksonville College, Winneshiek Medical Center, Molecular Templates (United States), Takeda (United States), Millennium Engineering and Integration (United States)

#Relapsed Or Refractory Multiple Myeloma #Millennium Pharmaceuticals + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Full Text